Immunology Market
A market in transition — from blockbuster biologics to oral small molecules and next-gen biologics
Market Overview
The immunology market is undergoing a generational shift as blockbuster biologics face biosimilar competition while novel oral therapies (JAK inhibitors, TYK2 inhibitors) and next-generation biologics (IL-23, IL-17, TL1A) emerge. The market spans autoimmune diseases including rheumatoid arthritis, psoriasis, IBD, and atopic dermatitis, with expanding indications and patient populations driving sustained growth despite biosimilar erosion.
Market Size Forecast (2024–2030)
Projected market value in USD billions
Market Segments
Share by therapeutic segment
Regional Market Analysis
Market share and growth by region
Key Drivers
- ▸Oral immunology therapies (JAK, TYK2 inhibitors) improving patient convenience and adherence
- ▸TL1A-targeting therapies emerging as potential best-in-class for IBD
- ▸Biosimilar erosion of Humira, Remicade, and Enbrel creating market share redistribution
- ▸Expanding indications for IL-23 and IL-17 inhibitors across multiple autoimmune diseases
- ▸Growing prevalence of autoimmune diseases globally
- ▸Personalized medicine approaches using biomarkers for therapy selection
Challenges
- ▸Biosimilar erosion reducing revenue for originator biologic franchises
- ▸JAK inhibitor safety concerns (VTE, malignancy, MACE) limiting uptake
- ▸Crowded competitive landscape in psoriasis and RA
- ▸Payer step-therapy and prior authorization requirements
- ▸High development costs for novel immunology mechanisms
Opportunities
- ▸TL1A inhibitors projected to create $5B+ IBD market segment
- ▸Oral immunology therapies capturing share from injectable biologics
- ▸Atopic dermatitis market expansion with novel non-steroidal options
- ▸Biosimilar switching creating $15B+ market share redistribution opportunity
- ▸Combination therapies and sequencing strategies extending product lifecycles
- ▸Emerging markets with low biologic penetration representing volume growth
Key Pipeline Drugs
Late-stage and recently approved therapies from Top 20 pharma
| Drug | Company | Phase |
|---|---|---|
RVT-3101 Ulcerative colitis, Crohn's disease | Roivant / Pfizer | Phase 3 |
Tulisokibart IBD | Johnson & Johnson | Phase 3 |
Deucravacitinib (SOTYKTU) Psoriasis, expanding to PsA, IBD | Bristol-Myers Squibb | Approved / Phase 3 |
Etrasimod (Velsipity) Ulcerative colitis | Pfizer | Approved |
Mirikizumab (Omvoh) UC, expanding to Crohn's | Eli Lilly | Approved / Phase 3 |
Bimekizumab (Bimzelx) Psoriasis, PsA, AS | UCB | Approved / Phase 3 |
Abrocitinib Atopic dermatitis | Pfizer | Approved |
Itepekimab COPD, asthma | Sanofi / Regeneron | Phase 3 |
Marketed Drugs — Current Landscape
Blockbuster and key marketed therapies shaping the competitive landscape
| Drug | Company | Annual Sales |
|---|---|---|
Humira (adalimumab) Facing biosimilar erosion | AbbVie | $14B+ (declining) |
Stelara (ustekinumab) Biosimilars approaching 2025 | Johnson & Johnson | $10B+ |
Skyrizi (risankizumab) Fast-growing IBD and psoriasis leader | AbbVie | $7B+ |
Dupixent (dupilumab) Expanding across multiple indications | Sanofi / Regeneron | $11B+ |
Cosentyx (secukinumab) Expanding indications | Novartis | $5B+ |
Rinvoq (upadacitinib) Expanding across immunology | AbbVie | $4B+ |
Tremfya (guselkumab) Growing with IBD expansion | Johnson & Johnson | $3B+ |
Ocrevus (ocrelizumab) MS leader | Roche | $6B+ |
Competitive Landscape
Tiered analysis of companies shaping the immunology market
Tier 1 — Immunology Leaders
Dominant biologic franchises with broad immunology portfolios
Tier 2 — Specialty Immunology
Strong positions in specific autoimmune indications
Tier 3 — Emerging Innovators
Novel mechanism leaders in TL1A and novel biologics
Our Research Methodology
KOL Network
45+ interviews with rheumatologists, dermatologists, gastroenterologists, and immunologists across US, EU5, and Japan.
Biosimilar Impact Modeling
Detailed analysis of biosimilar launch timelines, pricing erosion curves, and switching dynamics for Humira, Remicade, Enbrel, and Stelara.
Pipeline Analytics
Tracking of 500+ immunology pipeline assets with mechanism of action analysis and competitive positioning.
Payer & Access Analysis
Step-therapy and prior authorization analysis across US commercial, Medicare, and EU payer systems.
Patient Journey Mapping
Treatment sequencing analysis by indication with switching patterns and unmet need identification.
How We Help Clients Win in Immunology
Our consulting engagements combine deep therapeutic expertise with proprietary intelligence to identify where the opportunity lies — and how to capture it.
Biosimilar Defense Strategy
Protect your biologic franchise from biosimilar erosion with lifecycle management and indication extension
TL1A Market Entry
Position your TL1A inhibitor for success in the competitive IBD landscape
Oral Therapy Positioning
Strategic positioning of oral immunology therapies against injectable biologics
Indication Expansion Strategy
Identify and prioritize new indications for existing immunology assets
Frequently Asked Questions
How is the immunology market changing with biosimilars?
Biosimilars of Humira, Remicade, and Enbrel are causing significant market share redistribution. Stelara biosimilars are expected in 2025, creating both challenges for originators and opportunities for novel mechanism therapies.
What are the most promising emerging mechanisms in immunology?
TL1A inhibitors are the most promising for IBD, potentially creating a $5B+ market. TYK2 inhibitors are expanding beyond psoriasis. Novel oral therapies and targeted protein degraders are also emerging.
How can Medifirm help with immunology market strategy?
We provide comprehensive immunology market intelligence including biosimilar impact modeling, competitive landscape analysis, KOL engagement, payer access strategy, patient journey mapping, and pipeline gap analysis.